Loading
Atossa Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 May 2025.
Atossa Therapeutics, Inc.: what insiders have been doing
Atossa Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 10 filings came from 8 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Compared with its exchange (5,458 companies, median 22 filings), a count of 10 filings is below the norm. Over the whole record (from 2016), the tally stands at 6 purchases and 1 sale.
Insider buying of Atossa Therapeutics, Inc. has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
18
Thresholds
n/a
Buy Volume
€100,821
6 ops. · all time
Sell Volume
€29,876
1 ops. · all time
Who traded when
BuySaleH. Lawrence Remmel1 buy
Steven C. Quay1 buy
Since the insiders bought
- -60.2%Entry 12.45 · Close at T+365 4.95
- -60.2%Entry 13.50 · Close at T+365 5.37
- -40.4%Entry 22.65 · Close at T+365 13.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 14 May 2026
Declarations18 total
10,000 shares0Common StockSEC:0001193125-26-224148:0
10,000 shares0Common StockSEC:0001193125-26-224133:0
10,000 shares0Common StockSEC:0001193125-26-224125:0
10,000 shares0Common StockSEC:0001193125-26-224521:0
10,000 shares0Common StockSEC:0001193125-26-224140:0
10,000 shares0Common StockSEC:0001193125-26-224135:0
65,000 shares0Common StockSEC:0001193125-26-134861:0
63,000 shares0Common StockSEC:0001193125-26-132644:0
331,674 shares0Common StockSEC:0001193125-26-030571:0
325,203 shares0Common StockSEC:0001193125-26-019273:0
11,239 shares@ US$0.8797100.0% of flowCommon StockSEC:0000950170-25-076523:0
Canonical exit: 19 Aug 2025 (T+90)
10,000 shares@ US$0.70100.0% of flowCommon StockSEC:0000950170-25-046742:0
Canonical exit: 24 Jun 2025 (T+90)
25,000 shares@ US$1.77100.0% of flowCommon StockSEC:0000950170-24-043690:0
Canonical exit: 9 Jul 2024 (T+90)
50,000 shares@ US$0.6531.1% of flowCommon StockSEC:0001437749-23-032461:0
50,000 shares@ US$0.9746.2% of flowCommon StockSEC:0001437749-23-017896:0
Canonical exit: 18 Sept 2023 (T+90)
4,581 shares@ US$5.6422.7% of flowCommon StockSEC:0001437749-21-016573:0
50,000 sharesCommon StockSEC:0001144204-16-076463:0
Canonical exit: 18 Apr 2016 (T+90)
50,000 sharesCommon StockSEC:0001144204-16-076465:0
Canonical exit: 18 Apr 2016 (T+90)
18 of 18 declarations
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ticker: ATOS) is a U.S.-listed clinical-stage biopharmaceutical company quoted on NASDAQ in the United States. Headquartered in Seattle, Washington, Atossa was incorporated in April 2009 and originally focused on breast-health devices and diagnostic concepts before evolving into a drug-development company centered on oncology. For international investors, this is best viewed as a development-stage biotech rather than a revenue-generating pharmaceutical platform, which means valuation is primarily driven by clinical data, regulatory progress, intellectual property, and financing capacity.
The company’s lead asset is oral (Z)-endoxifen, the active metabolite of tamoxifen. Atossa is developing this proprietary compound across multiple breast-cancer settings, including risk reduction, neoadjuvant treatment in premenopausal women with ER+/HER2- disease, and a metastatic breast-cancer strategy that management has highlighted as potentially offering a more efficient regulatory path. The company has also expanded the potential utility of (Z)-endoxifen beyond oncology, notably into Duchenne muscular dystrophy, where it received meaningful FDA designations in late 2025 and early 2026. That broadens the narrative from a single oncology program to a potential platform asset, although the scientific and regulatory risk remains high.
Read moreShow less
Atossa’s competitive position is that of a niche, highly focused small-cap biotech operating in one of the most crowded therapeutic areas: breast cancer. Its differentiation is built around a proprietary molecule, a concentration on hormone-receptor-positive disease, biomarker-oriented development, and an attempt to streamline the path to approval through targeted clinical and regulatory interactions. In practice, Atossa competes indirectly with major oncology franchises from large-cap pharma as well as many other specialty biotechs pursuing endocrine, targeted, or biomarker-driven therapies. Because it lacks marketed products, the investment case depends on whether its clinical readouts can validate a distinct efficacy and safety profile.
Geographically, the business is centered in the United States, with Seattle serving as the corporate base, while its public market listing is NASDAQ in the United States. Recent milestones have included FDA discussions on the development strategy for (Z)-endoxifen, protocol refinement for the EVANGELINE study, and the receipt of FDA Rare Pediatric Disease and Orphan Drug designations for Duchenne muscular dystrophy. These events suggest an active regulatory agenda and a management team seeking multiple value-inflection points. Overall, Atossa remains a high-risk, high-upside clinical-stage oncology company whose near- to medium-term performance will be driven by trial execution and regulatory milestones rather than commercial sales.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
